Search Results for: -35or3cj.html

ACTUATE THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR  ELRAGLUSIB FOR TREATMENT OF PANCREATIC CANCER

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for elraglusib for treatment of patients with pancreatic cancer. Elraglusib (9-ING-41) is Actuate’s proprietary small molecule glycogen synthase kinase-3 beta (GSK-3β) inhibitor which is

ACTUATE THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR  ELRAGLUSIB FOR TREATMENT OF PANCREATIC CANCER Read More »

2023-ASCO-Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC).

Publications /

2023-ASCO-Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC). Read More »

ACTUATE THERAPEUTICS ANNOUNCESPOSTER PRESENTATIONS AT THE 2023 ASCO ANNUAL MEETING

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today four presentations from scientific collaborators at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting, taking place June 2 – 6, 2023, in Chicago, Illinois. The abstracts are currently available on the ASCO meeting website. The

ACTUATE THERAPEUTICS ANNOUNCESPOSTER PRESENTATIONS AT THE 2023 ASCO ANNUAL MEETING Read More »